Pituitary-Tumor Endocrinopathies Pituitary adenomas account for about 15% of intracranial
tumors. Clinical manifestations of disease reflect the oversecretion of the involved hormone …

abstract Objective: The aim was to formulate practice guidelines for the diagnosis and
treatment of hyperprolactinemia. Participants: The Task Force consisted of Endocrine …

Hyperprolactinemia is one of the most frequently diagnosed clinical disorders in routine
endocrine practice. Any process interfering with dopamine synthesis, its transport to the …

Prolactinomas are the most common pituitary adenomas (approximately 40% of cases), and
they represent an important cause of hypogonadism and infertility in both sexes. The …

Objective Cabergoline is a dopamine agonist used to treat hyperprolactinaemia. Because
hyperprolactinaemia is a significant cause of infertility in women, cabergoline and other …

Context: Cabergoline is effective for hyperprolactinemic hypogonadism. However, the rate of
cabergoline-induced pregnancy in women with prolactinoma remains unknown. Also …

Context A sex difference in the progression of prolactin (PRL) tumors has been disputed for
years. Objective To compare tumor characteristics and postoperative clinical course …

Despite the fact that consensus guidelines recommend long-term dopamine agonist (DA)
therapy as a first-line approach to the treatment of small prolactinoma, some patients …

Pituitary tumors, usually adenomas, account for about 10–15% of all intracranial tumors.
Their treatment, which includes surgery, medicine or radiotherapy, either isolated or in …

Context Prolactinoma is the most frequent pituitary tumour among women of child‐bearing
age. Only a few studies have addressed the outcome of prolactinoma after pregnancy …